This is an aggregated industry headline. Read the full story at BioPharma Dive →
Oberland pours up to $400M into MeiraGTx eye gene therapies
The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development - one of which MeiraGTx recently reacquired from J&J.
By BioPharma Dive
· Jul 7, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Novartis is executing more layoffs at its U.S. headquarters in East Hanover, New Jersey, handing 322 employees…
The WeekFierceBiotech ↗
AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challeng…
The WeekBriefing
Vertex’s Casgevy can now treat sickle cell disease and transfusion-dependent beta thalassemia in patients aged…